Our study shows that an oral IRAK4 degrader in development for TLR/IL-1R–driven autoimmune diseases has robust in vivo activity against the target and pathway in HVs and patients, with a favorable safety and tolerability profile. This evidence concerns the gene IRAK4 and autoimmune disease.